---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-043995"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:37:28.819009+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports Q2 2021 net loss $21.5M; cash runway into 2H 2023; NKX101 data by year-end

## Summary
- Net loss $21.5M ($0.66/share) for Q2 2021; R&D expenses $16.0M, G&A $5.7M.
- Cash, equivalents, restricted cash, and short-term investments $280.3M as of June 30, 2021.
- Initial Phase 1 data for NKX101 (CD33-targeted NK cell therapy) expected by end of 2021.
- NKX019 (CD19-targeted NK) Phase 1 patient dosing expected to start in 2H 2021.
- Collaboration with CRISPR Therapeutics to co-develop two CAR-NK candidates and license CRISPR/Cas9 gene editing.

## SEC filing metadata
- accession: 0001564590-21-043995
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000156459021043995/0001564590-21-043995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000156459021043995/nktx-8k_20210812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-043995
- JSON: https://secwatch.observer/filing/0001564590-21-043995.json
- Plain text: https://secwatch.observer/filing/0001564590-21-043995.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.